AZD1390, an ataxia telangiectasia mutated inhibitor, attenuates microglia-mediated neuroinflammation and ischemic brain injury.
Zhen LanLong-Jie QuYing LiangLi-Qiu ChenShuai XuJian-Wei GeZhi-Wei XueXin-Yu BaoSheng-Nan XiaHai-Yan YangJing HuangYun XuXiao-Lei ZhuPublished in: CNS neuroscience & therapeutics (2024)
AZD1390 suppressed NF-κB signaling pathway to alleviate ischemic brain injury in experimental stroke, and attenuated microglia activation and neuroinflammation, which indicated that AZD1390 might be an attractive agent for the treatment of ischemic stroke.
Keyphrases
- brain injury
- cerebral ischemia
- subarachnoid hemorrhage
- signaling pathway
- inflammatory response
- lps induced
- pi k akt
- atrial fibrillation
- neuropathic pain
- lipopolysaccharide induced
- epithelial mesenchymal transition
- oxidative stress
- early onset
- induced apoptosis
- traumatic brain injury
- combination therapy
- spinal cord
- ischemia reperfusion injury
- spinal cord injury
- cognitive impairment
- toll like receptor
- replacement therapy
- wild type
- smoking cessation